We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Vertex Pharmaceuticals on Wednesday announced that a three-drug regimen combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor met the primary endpoints of two Phase III studies in patients with cystic fibr